{"id":20380,"date":"2025-01-01T10:27:44","date_gmt":"2025-01-01T02:27:44","guid":{"rendered":"https:\/\/flcube.com\/?p=20380"},"modified":"2025-03-03T15:29:51","modified_gmt":"2025-03-03T07:29:51","slug":"beigene-secures-global-rights-to-duality-biologics-b7h4-targeted-adc-db1312-bg-c9074","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20380","title":{"rendered":"BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312\/BG-C9074"},"content":{"rendered":"\n

Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160<\/a>, SHA: 688235<\/a>, NASDAQ: BGNE<\/a>) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality’s B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.<\/p>\n\n\n\n

Terms of the Agreement and Financials<\/strong>
The exclusive option was initially granted to BeiGene in July 2023, allowing them to obtain a global clinical and commercial license for an investigational, preclinical ADC therapy intended for patients with select solid tumors. As part of the deal, Duality Biologics received an upfront payment and is eligible for additional payments upon the achievement of specific development, regulatory, and commercial milestones, totaling up to USD1.3 billion. This financial arrangement also includes tiered royalties on sales.<\/p>\n\n\n\n

Recent Milestone Achievements<\/strong>
In the current year, Duality Biologics has received an option exercise fee and a milestone payment based on the advancement of Phase I dose-escalation for DB1312\/BG-C9074. This progress underscores the momentum behind the development of the ADC and the potential for it to become a significant treatment option for patients with solid tumors.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States…<\/p>\n","protected":false},"author":1,"featured_media":20381,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,185,2092,232,3795,847,846,3046,848],"class_list":["post-20380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-beigene","tag-beone-medicines","tag-duality-biologics","tag-duality-biotherapeutics","tag-hkg-6160","tag-nasdaq-bgne","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"\nBeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20380\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20380\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-01T02:27:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T07:29:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"580\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312\\\/BG-C9074\",\"datePublished\":\"2025-01-01T02:27:44+00:00\",\"dateModified\":\"2025-03-03T07:29:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0102.png\",\"keywords\":[\"ADC \\\/ XDC\",\"BeiGene\",\"BeOne Medicines\",\"Duality Biologics\",\"Duality Biotherapeutics\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20380#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20380\",\"name\":\"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\\\/BG-C9074 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0102.png\",\"datePublished\":\"2025-01-01T02:27:44+00:00\",\"dateModified\":\"2025-03-03T07:29:51+00:00\",\"description\":\"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\\\/BG-C9074.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20380\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0102.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0102.png\",\"width\":1080,\"height\":580,\"caption\":\"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\\\/BG-C9074\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20380#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312\\\/BG-C9074\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074 - Insight, China's Pharmaceutical Industry","description":"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20380","og_locale":"en_US","og_type":"article","og_title":"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074","og_description":"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.","og_url":"https:\/\/flcube.com\/?p=20380","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-01T02:27:44+00:00","article_modified_time":"2025-03-03T07:29:51+00:00","og_image":[{"width":1080,"height":580,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20380#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20380"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312\/BG-C9074","datePublished":"2025-01-01T02:27:44+00:00","dateModified":"2025-03-03T07:29:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20380"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20380#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","keywords":["ADC \/ XDC","BeiGene","BeOne Medicines","Duality Biologics","Duality Biotherapeutics","HKG: 6160","NASDAQ: BGNE","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20380#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20380","url":"https:\/\/flcube.com\/?p=20380","name":"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20380#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20380#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","datePublished":"2025-01-01T02:27:44+00:00","dateModified":"2025-03-03T07:29:51+00:00","description":"Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States and China, has announced that BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has exercised its exclusive option to secure global development, manufacturing, and commercialization rights to Duality's B7H4 targeted antibody-drug conjugate (ADC), DB1312\/BG-C9074.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20380#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20380"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20380#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","width":1080,"height":580,"caption":"BeiGene Secures Global Rights to Duality Biologics' B7H4 Targeted ADC DB1312\/BG-C9074"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20380#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312\/BG-C9074"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0102.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20380"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20380\/revisions"}],"predecessor-version":[{"id":20382,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20380\/revisions\/20382"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20381"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}